About SINCO PHARMA Company

As a leading marketing, promotion and channel management service provider, the Group focuses on blood products with rich experience in imported pharmaceutical distribution, and provides comprehensive marketing, promotion and channel management services to overseas small and medium-sized pharmaceutical companies based on a marketing and promotion network covering the whole of China. The Group's products are imported from well-known overseas pharmaceutical companies, and the product portfolio mainly covers prescription drugs such as blood products and anti-infective drugs. The marketing and promotion services provided by the Group include: coordinating and cooperating with overseas pharmaceutical companies to carry out import registration/re-registration work and other regulatory agency requirements; formulating customized marketing and marketing strategies based on consideration of product treatment fields, product characteristics, regulatory environment, market needs and other commercial factors; selecting, appointing and managing third party service promoters; organizing academic conferences, lectures, seminars and other promotional activities; and communicating to physicians about the medical uses and benefits of the Group's products. The channel management services provided by the Group include: customs clearance and inspection of products; cooperation with third parties to carry out logistics distribution work; participation in tenders; confirmation of purchase orders, product delivery and collection work of third party commercial pharmaceutical distribution companies; collection and analysis of sales data; and management and improvement of the inventory volume of commercial distribution channels. The Group selects high-quality blood products from overseas markets to make up for the pharmaceutical needs that have yet to be met in the domestic market; with the excellent clinical effects of the products, it ensures that it has strong growth potential in the Chinese pharmaceutical industry. The Group is also continuing to promote industrial deployment in the medical and aesthetic field. While medical and aesthetic R&D projects are progressing steadily, the Group's product production line construction and medical and aesthetic team recruitment have all been carried out smoothly in the first half of 2022.